NNR THERAPEUTICS Trademark

Trademark Overview

On Monday, September 11, 2006, a trademark application was filed for NNR THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the NNR THERAPEUTICS trademark a serial number of 78970985. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Monday, April 6, 2009. This trademark is owned by Targacept, Inc.. The NNR THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, inflammatory diseases and disorders, and addictions
nnr therapeutics

General Information

Serial Number78970985
Word MarkNNR THERAPEUTICS
Filing DateMonday, September 11, 2006
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateMonday, April 6, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of central nervous system diseases and disorders, inflammatory diseases and disorders, and addictions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 15, 2006
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTargacept, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWinston-Salem, NC 27101

Trademark Events

Event DateEvent Description
Monday, April 6, 2009ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, April 6, 2009ABANDONMENT - AFTER EX PARTE APPEAL
Monday, April 6, 2009EXPARTE APPEAL TERMINATED
Wednesday, January 21, 2009EX PARTE APPEAL-REFUSAL AFFIRMED
Monday, November 3, 2008NOTIFICATION OF EXAMINERS STATEMENT E-MAILED
Monday, November 3, 2008EXAMINERS STATEMENT E-MAILED
Monday, November 3, 2008EXAMINERS STATEMENT - COMPLETED
Monday, September 8, 2008JURISDICTION RESTORED TO EXAMINING ATTORNEY
Monday, August 25, 2008EXPARTE APPEAL DSMSED - FAILURE TO FILE BRIEF
Sunday, June 29, 2008NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Sunday, June 29, 2008ACTION DENYING REQ FOR RECON E-MAILED
Sunday, June 29, 2008ACTION CONTINUING FINAL - COMPLETED
Wednesday, June 18, 2008JURISDICTION RESTORED TO EXAMINING ATTORNEY
Saturday, April 5, 2008NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Saturday, April 5, 2008ACTION DENYING REQ FOR RECON E-MAILED
Saturday, April 5, 2008ACTION CONTINUING FINAL - COMPLETED
Wednesday, March 26, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 26, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 26, 2008ASSIGNED TO LIE
Thursday, March 13, 2008TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, March 13, 2008EX PARTE APPEAL-INSTITUTED
Thursday, March 13, 2008JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, March 13, 2008EXPARTE APPEAL RECEIVED AT TTAB
Thursday, September 13, 2007NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, September 13, 2007FINAL REFUSAL E-MAILED
Thursday, September 13, 2007FINAL REFUSAL WRITTEN
Saturday, September 8, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 2, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 2, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 2, 2007NON-FINAL ACTION E-MAILED
Friday, February 2, 2007NON-FINAL ACTION WRITTEN
Friday, February 2, 2007ASSIGNED TO EXAMINER
Friday, September 15, 2006NEW APPLICATION ENTERED IN TRAM

Related Keywords

therapeutics diseases disorders inflammatory addictions system nervous preparations treatment central pharmaceutical